Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT05479981 Active, not recruiting - Clinical trials for Nervous System Diseases

Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients

MARINA-OLE
Start date: August 4, 2022
Phase: Phase 2
Study type: Interventional

AOC 1001-CS2 (MARINA-OLE) is a Phase 2 extension of the AOC 1001-CS1 (MARINA) study to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of multiple-doses of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) patients

NCT ID: NCT05479721 Active, not recruiting - NAFLD Clinical Trials

LITMUS Imaging Study

Start date: September 4, 2019
Phase:
Study type: Observational

The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD). It aims to evaluate the diagnostic performance of imaging biomarkers (ultrasound elastography and magnetic resonance biomarkers) against NAFLD histological scores in a cross-sectional analysis and the natural history of NAFLD in a longitudinal study.

NCT ID: NCT05478161 Active, not recruiting - Clinical trials for Transcatheter Aortic Valve Implantation

Investigation of the ALLEGRA THV System With a New Delivery System in Patients With Aortic Stenosis or Failed Surgical Bioprosthesis

EMPIRE
Start date: January 24, 2023
Phase: N/A
Study type: Interventional

The EMPIRE study confirms the technical performance of the new IMPERIA Delivery System and evaluates the safety and efficacy of the entire ALLEGRA THV System. The primary endpoint is device success rate at 7 days (discharge from index procedure or 7 days post implant, whichever comes first), as defined by VARC 2. Based on the outcomes of a study with a similar device and considering a drop-out rate of 5%, 107 patients need to be enrolled in the study.

NCT ID: NCT05477576 Active, not recruiting - Clinical trials for Neuroendocrine Tumors

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

ACTION-1
Start date: March 24, 2022
Phase: Phase 3
Study type: Interventional

This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity [HA]-DOTATATE.

NCT ID: NCT05471921 Active, not recruiting - Clinical trials for Alcohol and Substance-Related Mental Disorders

Effectiveness of an Evidence-based Stepped Care System for Alcohol and Other Drug Use Problems Among Congolese Refugees in Zambia

Start date: April 26, 2023
Phase: N/A
Study type: Interventional

This is a randomized controlled trial (RCT) evaluating the effectiveness of a screening, brief intervention, and referral to treatment (SBIRT) stepped-care system in reducing unhealthy AOD use among Congolese refugees and the host community in Mantapala, an integrated settlement in northern Zambia.

NCT ID: NCT05468294 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer (NSCLC)

F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer

Nivokin
Start date: March 9, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Prospective, open label, non-randomized, phase I/IIb study of F16IL2 in combination with Nivolumab.

NCT ID: NCT05464147 Active, not recruiting - Clinical trials for Coronary Artery Disease

DYNAMX Bioadaptor ImplanTation for the trEatment of Complex Coronary Lesions

DYNAMITE
Start date: October 19, 2021
Phase: N/A
Study type: Interventional

The aim of the DYNAMITE study is to investigate the (a) acute procedural and (b) 9-month follow-up performance of DynamX Drug-Eluting Coronary Bioadaptor System implantation in complex coronary lesions.

NCT ID: NCT05462730 Active, not recruiting - Clinical trials for Inflammatory Response

Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction

PULSE-MI
Start date: November 14, 2022
Phase: Phase 2
Study type: Interventional

The overall primary objective of the PULSE-MI trial is to test the hypothesis that administration of single-dose glucocorticoid pulse therapy in the pre-hospital setting reduces final infarct size in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI)

NCT ID: NCT05462717 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Start date: September 19, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.

NCT ID: NCT05459415 Active, not recruiting - Clinical trials for Squamous Cell Carcinoma of Head and Neck

Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCC

Start date: June 22, 2022
Phase: N/A
Study type: Interventional

This study aims to explore the 2-year DFS (disease-free survival) rate and organ retention rate and to explore the ORR, PCR rate, 2y-OS, and quality of life of patients.